CJ Bioscience (311690) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, CJ Bioscience (311690) reported revenue of 3.7 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
20253.7 billion KRW-24.8 billion KRW-24.0 billion KRW[source]
20243.5 billion KRW-34.2 billion KRW-32.8 billion KRW[source]
20235.6 billion KRW-32.1 billion KRW-22.9 billion KRW[source]
20224.1 billion KRW-33.2 billion KRW-34.9 billion KRW[source]
20214.4 billion KRW-10.1 billion KRW-19.3 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
202571.7 billion KRW11.2 billion KRW60.5 billion KRW[source]
202498.0 billion KRW14.4 billion KRW83.6 billion KRW[source]
202389.2 billion KRW14.8 billion KRW74.5 billion KRW[source]
202288.5 billion KRW37.8 billion KRW50.7 billion KRW[source]
2021115.1 billion KRW27.2 billion KRW87.9 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice